Literature DB >> 8354159

Is fine needle aspiration biopsy of salivary gland masses really necessary?

A Candel1, P Gattuso, V Reddy, G Matz, M Castelli.   

Abstract

The use of fine needle aspirate biopsies (FNAB's) in the outpatient setting has progressively escalated, particularly in the area of head and neck pathology. An increasing percentage of these are for salivary gland masses. We present our experience with salivary gland FNAB's at our institution for four years, from 1988-1992. One thousand and twenty-two (1,022) FNAB's of superficial masses were performed by two pathologists. One hundred sixty-three (15.9%) were salivary gland biopsies. Of these 163 cases, 21 (12.9%) were normal tissue, 77 (47.2%) were inflammatory processes, 50 (30.7%) were benign tumors, and 15 (9.2%) were malignant tumors. None of the aspirates were unsatisfactory. Tissue correlation was possible in 47 (28.8%) cases. Two false negative cases (4.3%) were identified; these were a Warthin's tumor diagnosed as chronic sialoadenitis by FNAB; and a poorly differentiated squamous cell carcinoma diagnosed as adenocarcinoma by FNAB. There were no false positive cases. Overall sensitivity was 95.7% and specificity was 100%. Our experience indicates that FNAB of salivary glands is an effective screening procedure in evaluating salivary gland masses. The cytologic diagnosis may assist the clinician in allaying patients' anxieties, as well as in further collateral workup prior to definitive therapy.

Entities:  

Mesh:

Year:  1993        PMID: 8354159

Source DB:  PubMed          Journal:  Ear Nose Throat J        ISSN: 0145-5613            Impact factor:   1.697


  2 in total

1.  Role of fine-needle aspiration cytology in swellings of the parotid region.

Authors:  Basavanandswami Hartimath; Annappa Kudva; Abhimanyu Singh Rathore
Journal:  Indian J Surg       Date:  2010-12-17       Impact factor: 0.656

2.  An audit of surgery of the parotid gland.

Authors:  G T Deans; K Briggs; R A Spence
Journal:  Ann R Coll Surg Engl       Date:  1995-05       Impact factor: 1.891

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.